Rodman & Renshaw Highlights (Z)-Endoxifen Potential as It Initiates Buy on Atossa Therapeutics

Rodman & Renshaw assigns Buy rating and $12 PT on (Z)-endoxifen, highlighting breast cancer program and rare disease upside.